Voyager Therapeutics Inc. (VYGR) is a pioneering clinical-stage gene therapy company headquartered in Cambridge, Massachusetts, dedicated to addressing severe neurological disorders through its innovative adeno-associated virus (AAV) platform. The company is actively advancing a robust pipeline of investigational therapies aimed at delivering targeted gene treatments that may significantly alter the treatment landscape for patients with debilitating central nervous system conditions. With strategic collaborations and a commitment to addressing substantial unmet medical needs, Voyager is positioned as a leader in neurology, poised to make a meaningful impact on patient care and outcomes in this critical area of healthcare. Show more

Location: 75 HAYDEN AVENUE, LEXINGTON, MA, UNITED STATES, 02421, Lexington, MA, 02421, USA | Website: https://www.voyagertherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

215.2M

52 Wk Range

$2.65 - $5.78

Previous Close

$3.98

Open

$3.94

Volume

1,017,189

Day Range

$3.81 - $4.03

Enterprise Value

206.1M

Cash

45.13M

Avg Qtr Burn

-31.05M

Insider Ownership

16.12%

Institutional Own.

57.06%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AAV Capsids (Pfizer) Details Neurological disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AAV Capsids (Novartis) Details Cardiovascular disease , Neurological disorder	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AAV Capsids Details Cardiovascular disease , Neurological disorder	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AAV Capsids + ZF-TRs (Sangamo) Details Prion disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VY7523 (formerly VT- TAU01) [anti-tau antibody] Details Alzheimer's disease	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VY9323 (SOD1 silencing gene therapy) Details Neurodegenerative disease, Amyotrophic lateral sclerosis	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VY1706 (Tau-silencing Gene Therapy) Details No identified indication yet	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GBA1 gene therapy program Details Parkinson's disease, Central nervous system illness	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VY-HTT01 Details Huntington's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VY-AADC (NBIb-1817) Details Parkinson's disease, Central nervous system illness	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.